OGN — Organon & Co.

—
NYSE · Health Care · Pharmaceuticals · CIK 1821825 ·
Last close
$13.73
Market Cap
$3.61B
52W High
$13.78
52W Low
$5.67
ADV30
2,900,947
Next earnings
2026-11-09

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 1,558,000,000 847,000,000 323,000,000 108,000,000 13,178,000,000 1,132,000,000 12,172,000,000
Mar 2026 1,460,000,000 783,000,000 266,000,000 146,000,000 12,996,000,000 1,116,000,000 12,093,000,000
Dec 2025 1,507,000,000 741,000,000 217,000,000 -205,000,000 12,867,000,000 574,000,000 12,115,000,000
Sep 2025 1,602,000,000 857,000,000 358,000,000 160,000,000 13,552,000,000 672,000,000 12,646,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$737,000,000
Investing CF
$130,000,000
Financing CF
$-313,000,000
CapEx
$-303,000,000
Dividends Paid
$-18,000,000
Buybacks
—
EPS Diluted TTM
$0.77
As of
2026-08-02

Balance + Analyst (yfinance extras)

Retained Earnings
$1,352,000,000
Inventory
$1,351,000,000
Receivables
$1,492,000,000
ST Investments
—
EBIT TTM
$959,000,000
Pretax Income TTM
$491,000,000
Interest Exp TTM
$468,000,000
Analysts
4

Yahoo Snapshot (yfinance, live)

Total Revenue
$6,127,000,064
EBITDA
$1,564,000,000
Free Cash Flow
$490,750,016
Enterprise Value
$11,002,992,640
Total Cash
$1,132,000,000
Total Debt
$8,552,999,936
Shares Out
262,609,433
Trailing EPS
$0.78
Book Value
$3.83
ROE
24.0%
ROA
5.7%
Div Yield
0.59%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 6,216,000,000 1,226,000,000 187,000,000 12,867,000,000 12,115,000,000 752,000,000 700,000,000
Dec 2024 6,403,000,000 1,486,000,000 864,000,000 13,101,000,000 12,629,000,000 472,000,000 939,000,000
Dec 2023 6,263,000,000 1,327,000,000 1,023,000,000 12,058,000,000 12,128,000,000 -70,000,000 799,000,000
Dec 2022 6,174,000,000 1,705,000,000 917,000,000 10,955,000,000 11,847,000,000 -892,000,000 858,000,000

TTM Snapshot

Revenues TTM
$6,263,000,000
NetIncome TTM
$803,000,000
OpCashFlow TTM
$0
Assets (Latest)
$13,101,000,000
Forward EPS
$3.62

Max Pain — expiry 2026-12-18

max pain strike: $10.00 · spot: $13.73 · call oi: 3,984 · put oi: 1,367
Expected Move to 2026-12-18: ±$0.45 (3.28%) — implied range $13.28 – $14.18 · ATM straddle on $14.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
KNSA Kiniksa Pharmaceuticals International, plc $3.63B $75.08 —
XENE Xenon Pharmaceuticals Inc. $3.58B $36.94 —
ACAD ACADIA PHARMACEUTICALS INC $3.56B $20.68 —
IDYA IDEAYA Biosciences, Inc. $3.54B $36.69 —
LEGN Legend Biotech Corp $3.72B $19.11 —

News headlines (Yahoo Finance, 1h cache)

Why Organon (OGN) Is Getting Attention Today
2026-09-22 12:15 · Yahoo
Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device
2026-09-22 03:24 · Yahoo
PhaseV Appoints Biopharma Leaders Klaus Beck and Avi Kulkarni to Scientific Advisory Board to Guide Expansion of AI Conductor
2026-09-16 12:30 · Yahoo
Arletta Pharma Solutions Appoints Jeannette Jager-van Dijk as Chief Executive Officer
2026-09-01 11:18 · Yahoo
The Surprising Pockmarks On Cooper's Earnings That Caused Its Stock To Dive
2026-09-10 20:18 · Yahoo
Is Trending Stock Organon & Co. (OGN) a Buy Now?
2026-09-21 13:00 · Yahoo
Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device
2026-09-14 11:30 · Yahoo
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
2026-09-08 13:00 · Yahoo
Orogen Royalties Acquires Two Gold Projects in Southwest Utah
2026-09-02 12:00 · Yahoo
National Can-RISE Study to Help Close Critical Gaps in Menopause Research
2026-08-27 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.